Donnez Jacques
Société de Recherche pour l'Infertilité (SRI), 1150 Brussels, Belgium.
Université Catholique de Louvain, 1200 Brussels, Belgium.
J Clin Med. 2020 Dec 5;9(12):3948. doi: 10.3390/jcm9123948.
The objective of this review is to determine the evidence or, conversely, the absence of evidence regarding the effectiveness of progestogens in treating premenopausal women with uterine fibroids. In particular, the goal is to address recurring questions as to whether they are effective or not for managing symptoms commonly attributed to fibroids.
A review of the most relevant papers ( = 63) on the efficacy of progesterone and progestogens as medical therapy for uterine fibroids.
Having reviewed the most significant papers on the relationship between uterine fibroids and progesterone/progestogens, it is clear that there is biochemical, histological and clinical evidence that progesterone and progestogens play a critical role in the pathogenesis of myomas.
Since progesterone is already implicated in the pathogenesis of this entity, using progestogens to manage fibroids is like constantly adding fuel to the fire, rendering this treatment ineffective.
本综述的目的是确定关于孕激素治疗绝经前子宫肌瘤女性有效性的证据，或者相反，确定缺乏此类证据。特别是，目标是解决关于它们对通常归因于肌瘤的症状管理是否有效的反复出现的问题。
对关于孕酮和孕激素作为子宫肌瘤药物治疗疗效的最相关论文（共63篇）进行综述。
在回顾了关于子宫肌瘤与孕酮 / 孕激素之间关系的最重要论文后，很明显有生化、组织学和临床证据表明孕酮和孕激素在肌瘤发病机制中起关键作用。
由于孕酮已经与该病症的发病机制有关，使用孕激素治疗肌瘤就如同不断火上浇油，使这种治疗无效。
